A Prospective, Randomized, Double Blinded, Multicenter and Therapeutic Exploratory Study to Comparatively Assess Efficacy and Safety of CWP-0403 in Type 2 Diabetes Patients Who Are Insufficiently Controlled by Diet and Exercise.
Phase of Trial: Phase II
Latest Information Update: 18 Jun 2014
At a glance
- Drugs Anagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors JW Pharmaceutical
- 23 Jul 2012 JW Pharmaceutical added as association as reported by ClinicalTrials.gov.
- 24 Nov 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 04 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.